Collection episode 03 · 2:10 · English
Peptides in 2TM · Ipamorelin
Ipamorelin: A Different Route to Growth Hormone
Five amino acids can trigger a measurable hormone response. Whether that response becomes a useful treatment depends on what happens next in people.
Ipamorelin is a synthetic pentapeptide investigated as a growth-hormone secretagogue and ghrelin-receptor agonist. This episode traces its Danish development, the animal experiments that attracted attention, early human pharmacology and a later trial in patients recovering from bowel surgery. Each finding answers a different question.
English narration with optional English captions.
Inside the film
Select a time to play from that point.
- Introduction
- Five-amino-acid design
- Danish discovery
- Receptor pathways
- Animal selectivity
- Human pharmacology
- Bowel-recovery trial
- Interpreting the findings
- U.S. regulatory context
From Danish discovery to human evidence
A Danish discovery team
Kirsten Raun and colleagues at Novo Nordisk's Department of GH Biology in Måløv, Denmark, reported ipamorelin's pharmacology in the November 1998 European Journal of Endocrinology. The coauthors were B. S. Hansen, N. L. Johansen, H. Thøgersen, K. Madsen, M. Ankersen and P. H. Andersen. [1]
The researchers described a compound identified through a medicinal-chemistry program derived from earlier growth-hormone-releasing peptides. Work on compounds derived from ipamorelin was also published in 1998. The film uses 1998 as the year of the landmark published discovery work. The paper's affiliation is Novo Nordisk, a company research group. [1, 7]
As of November 2026, almost 28 years have elapsed since the landmark pharmacology publication. That span describes the history of research, rather than continuous large clinical trials or decades of established patient benefit.
Five amino acids, one signaling route
The sequence is Aib–His–D-2-Nal–D-Phe–Lys–NH₂. Its composition includes nonstandard residues. PubChem identifies the free-base compound as CID 9831659, molecular formula C₃₈H₄₉N₉O₅. An acetate preparation has additional counterion components, so its formula should be identified separately. [1, 6]
The original experiments showed activity through a growth-hormone secretagogue receptor pathway. In modern terminology, ipamorelin activates the ghrelin receptor, GHS-R1a. Pituitary growth-hormone release is one measurable consequence. The receptor mechanism does not itself quantify a long-term health outcome. [1–3]
CJC-1295 and tesamorelin are GHRH analogues and act through the GHRH receptor. Older experiments with GHRH and other secretagogues show that the pathways can interact. Those experiments must retain their actual agents, populations, routes and endpoints when discussed. A result involving GHRP-6 does not supply a clinical effect estimate for an ipamorelin/CJC-1295 or ipamorelin/tesamorelin preparation. [8]
What the original animal experiments found
The 1998 report included rat pituitary cells, anesthetized rats and conscious pigs. In pigs, ipamorelin released growth hormone without raising ACTH and cortisol above the levels observed after GHRH stimulation in the same way that GHRP-2 and GHRP-6 did. That selective response helped motivate further development. It remains a finding in those animal experiments. It cannot establish that cortisol is unaffected in every person, exposure or combination. [1]
What was measured in healthy men
The 1999 study used a dose-escalation design with eight healthy male subjects at each of five intravenous infusion levels. The report describes a single episode of growth-hormone release, peaking at approximately 0.67 hours, or 40 minutes. It also modeled drug exposure and the hormone response. [2]
The film's circular timing graphic presents the reported peak time. It does not reconstruct individual patient curves or display unreported concentrations. The trial's endpoints were short-term pharmacology. Improvements in sleep, strength, recovery or longevity require outcome-specific evidence.
A randomized clinical question in the gut
A multicenter, double-blind phase 2 trial investigated ipamorelin after small- or large-bowel resection. It enrolled 117 patients, with 114 in the reported safety and modified intention-to-treat populations. The key efficacy endpoint was the time from the first study dose to tolerating a standardized solid meal. [3]
The meal-time comparison had P = 0.15. The trial did not establish a statistically significant improvement on that endpoint. The numerical difference is 7.3 hours, but the film does not present it as an established treatment benefit. The adverse-event percentages come from a surgical population and do not establish comparative safety for other uses. [3]
The chart starts at zero, uses the reported medians and shows the P value. No confidence interval has been invented. Enrollment and analysis populations are distinguished in the accompanying text.
Evidence at a glance
| Question and evidence | What researchers did | What they found | How to read it |
|---|---|---|---|
| Growth-hormone response | What researchers did1998 cell/animal experiments and a 1999 intravenous study in healthy men. | What they foundA measurable, short-term GH response; the human peak was approximately 0.67 hours. | How to read itA hormone endpoint does not establish improved sleep, strength, recovery or longevity. Human pharmacology report |
| Selective hormone response | What researchers didCompared GH, ACTH and cortisol in pigs under the tested conditions. | What they foundSelectivity relative to the older agents compared in the report. | How to read itThese are animal findings and cannot establish an absence of cortisol effects in every person or combination. Original pharmacology paper |
| Bowel-recovery trial | What researchers didDouble-blind randomized trial after bowel resection: 117 enrolled, 114 in the reported safety and modified intention-to-treat populations. | What they foundMedian first tolerated meal: 25.3 hours with ipamorelin versus 32.6 hours with placebo; P = 0.15. Any treatment-emergent adverse event: 87.5% versus 94.8%. | How to read itThe principal meal-time comparison did not establish a statistically significant benefit. Adverse-event percentages in surgical patients do not establish comparative safety for other uses. Trial report and population |
| Combination claims | What researchers didMechanistic context and older agent-specific GHRP/GHRH experiments. | What they foundDifferent signaling pathways can interact. | How to read itA GHRP-6 result cannot supply an effect estimate for an ipamorelin/CJC-1295 or ipamorelin/tesamorelin preparation. Actual agents studied |
| U.S. approval search | What researchers didFDA assessment and Drugs@FDA ingredient search, checked November 17, 2026. | What they foundNo ipamorelin drug approval identified. | How to read itU.S. scope and a dated search; compounding policy is a separate question. FDA scientific assessment |
Safety and U.S. regulatory context
Checked November 17, 2026. FDA's 2024 compounding assessment states that there are no FDA-approved drug products containing ipamorelin free base or ipamorelin acetate. A current openFDA Drugs@FDA ingredient query for IPAMORELIN returned no matches. This is a dated U.S. search and does not describe every jurisdiction. [4]
FDA's safety-risk page lists ipamorelin acetate under the 503B Category 2 interim policy and also discusses its withdrawn nomination under 503A. FDA identifies potential immunogenicity, aggregation and peptide-related impurities, and limited safety information for some injectable routes. [5]
The FDA briefing reviews serious adverse events, including deaths, in the postoperative research. It explicitly states that whether the deaths were related to ipamorelin is unclear. Attribution to the drug cannot be assumed. The safety warnings warrant accurate context, including the postoperative patient population and the limitations of the available data. [4, 5]
The October 2026 HHS enforcement-discretion policy is a separate, condition-specific compounding policy. Its Appendix A names BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is absent from that list. The policy should not be described as approving ipamorelin or every peptide preparation. The source is included for the website regulatory discussion, rather than added to the approved narration. [9]
Questions that remain
- Outcome-specific evidence. Which potential benefits have been tested directly in the intended population? How durable are any effects? What adverse events emerge with longer exposure? What does the exact formulation contain, and what evidence applies to it? These questions need agent-specific and outcome-specific studies.
- Review scope and status. This episode does not perform a systematic review of every use. Its source checks cover the discovery paper, the human pharmacology report, the postoperative randomized trial, chemical identity and the named U.S. regulatory sources. Full methods and supplements were not independently adjudicated across all studies. Reviewer status is AI-assisted source verification. Independent human scientific review is not recorded.
Continue with the Ipamorelin scientific record, or explore the related CJC-1295 film and Tesamorelin film.
The complete English transcript
What if a tiny peptide could ask the pituitary gland to release growth hormone?
Meet ipamorelin: five amino acids designed to trigger that signal.
In 1998, Kirsten Raun and colleagues at Novo Nordisk in Denmark reported its discovery. Researchers have studied it for almost three decades.
Ipamorelin activates the ghrelin receptor, part of the body's growth-hormone signaling system. CJC-1295 and tesamorelin act through a different receptor, the growth-hormone-releasing hormone receptor.
In the original pig experiments, ipamorelin stimulated growth hormone without the same rise in cortisol seen with some older secretagogues. That selectivity attracted interest.
A 1999 study in healthy men then showed a brief growth-hormone response after intravenous ipamorelin. It measured hormone release, leaving long-term health benefits unanswered.
Researchers also explored ghrelin signaling in the gut. A randomized trial enrolled 117 bowel-surgery patients. The ipamorelin group tolerated a meal sooner numerically, but the difference was not statistically significant.
So where do the muscle, sleep and anti-aging claims fit? A hormone response alone cannot establish those benefits. Different receptor pathways also cannot tell us how much benefit a particular peptide combination provides.
As of November 2026, ipamorelin has no FDA-approved medicine. FDA has raised concerns about immune reactions, peptide impurities and limited safety evidence.
Its story connects molecular design, human hormone measurements and an unfinished clinical question: which effects translate into meaningful benefits?
World Peptide Foundation. Peptides in 2. Every experience matters.
Published at the owner’s request. Technical media checks passed. Owner listening and pronunciation review are pending; independent human scientific review is not recorded.
Original sources & further reading
- [1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139:552–561. DOI 10.1530/eje.0.1390552. PMID 9849822.
- [2] Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16:1412–1416. DOI 10.1023/A:1018955126402. PMID 10496658.
- [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. Published online 2014. DOI 10.1007/s00384-014-2030-8. PMID 25331030.
- [4] FDA. October 29, 2024 Pharmacy Compounding Advisory Committee briefing, ipamorelin section.
- [5] FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Ipamorelin acetate entries.
- [6] PubChem. Ipamorelin, CID 9831659.
- [7] Ankersen M et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry. 1998. DOI 10.1021/jm9801962. PMID 9733495.
- [8] Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 1990. PMID 2108187.
- [9] HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026, Appendix A.
Synthetic-content disclosure
Narration is synthetic, using Tom. Eight original generated images illustrate anatomy, cellular biology, Denmark and research settings. Generated campus and laboratory views evoke the place and period; they are not archival photographs of the actual discovery site. The scientist is credited by name; no generated portrait is presented as Kirsten Raun. Receptor artwork illustrates the mechanism and is not a validated ligand-bound structure. The rotating chemical model is computed from PubChem's stereochemical SMILES using RDKit and is not an experimentally measured conformation. Charts use the cited reported quantities. The established Peptides in 2 opening and closing artwork is reused as the series identity. There is no added music.